Amylyx: Gubra A/S Announces New Collaboration with Amylyx Pharmaceuticals, Inc. to Develop a Novel Long-Acting GLP-1 Receptor Antagonist

Gubra A/S announced a collaboration with Amylyx Pharmaceuticals, Inc. for the development of a potential novel long-acting GLP-1 receptor antagonist. This collaboration brings together Gubra's expertise in quickly screening and identifying potent peptide therapeutics and Amylyx' expertise in developing novel therapies for communities with high unmet needs. At the end of the screening period, Gubra and Amylyx anticipate identifying a lead development candidate to enter Investigational New Drug (IND)-enabling studies. Amylyx then has the option to lead development once the drug peptide therapeutic has been identified. Under the agreement, Gubra will receive upfront and research payments and may receive more than $50 million in success-based development and commercialization milestones plus mid- single digit royalties on worldwide net sales. Gubra A/S announced a collaboration with Amylyx Pharmaceuticals, Inc. for the development of a potential novel long-acting GLP-1 receptor antagonist. This collaboration brings together Gubra's expertise in quickly screening and identifying potent peptide therapeutics and Amylyx' expertise in developing novel therapies for communities with high unmet needs. At the end of the screening period, Gubra and Amylyx anticipate identifying a lead development candidate to enter Investigational New Drug (IND)-enabling studies. Amylyx then has the option to lead development once the drug peptide therapeutic has been identified. Under the agreement, Gubra will receive upfront and research payments and may receive more than $50 million in success-based development and commercialization milestones plus mid- single digit royalties on worldwide net sales.